Mast Cell Chymase Antibody [C20M13]

Application: Reactivity: Human

Immunohistochemical analysis of formalin fixed paraffin embedded human colon tissue with F8677 at 1:50 dilution.

Usage Information

Dilution
IHC1:50 - 1:200

Application
IHC

Reactivity
Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
27 kDa

Positive Control	Human prostate adenocarcinoma; Human urothelial carcinoma; Human breast adenocarcinoma; Human endometrioid adenocarcinoma; Normal human colon; Normal human thymus; Normal human small intestine; Normal human esophagus; Human thymoma; Normal human uterus; Normal human lymph node; Normal human urothelial carcinoma; Normal human esophagus
Negative Control

Experimental Methods

IHC
Experimental Protocol： Deparaffinization/Rehydration 1. Deparaffinize/hydrate sections: 2. Incubate sections in three washes of xylene for 5 min each. 3. Incubate sections in two washes of 100% ethanol for 10 min each. 4. Incubate sections in two washes of 95% ethanol for 10 min each. 5. Wash sections two times in dH2O for 5 min each. 6.Antigen retrieval: For Citrate: Heat slides in a microwave submersed in 1X citrate unmasking solution until boiling is initiated; continue with 10 min at a sub-boiling temperature (95°-98°C). Cool slides on bench top for 30 min. Staining 1. Wash sections in dH2O three times for 5 min each. 2. Incubate sections in 3% hydrogen peroxide for 10 min. 3. Wash sections in dH2O two times for 5 min each. 4. Wash sections in wash buffer for 5 min. 5. Block each section with 100–400 µl of blocking solution for 1 hr at room temperature. 6. Remove blocking solution and add 100–400 µl primary antibody diluent in to each section. Incubate overnight at 4°C. 7. Remove antibody solution and wash sections with wash buffer three times for 5 min each. 8. Cover section with 1–3 drops HRPas needed. Incubate in a humidified chamber for 30 min at room temperature. 9. Wash sections three times with wash buffer for 5 min each. 10. Add DAB Chromogen Concentrate to DAB Diluent and mix well before use. 11. Apply 100–400 µl DAB to each section and monitor closely. 1–10 min generally provides an acceptable staining intensity. 12. Immerse slides in dH2O. 13. If desired, counterstain sections with hematoxylin. 14. Wash sections in dH2O two times for 5 min each. 15. Dehydrate sections: Incubate sections in 95% ethanol two times for 10 sec each; Repeat in 100% ethanol, incubating sections two times for 10 sec each; Repeat in xylene, incubating sections two times for 10 sec each. 16. Mount sections with coverslips and mounting medium.

IHC

Experimental Protocol：

Deparaffinization/Rehydration

1. Deparaffinize/hydrate sections:

2. Incubate sections in three washes of xylene for 5 min each.

3. Incubate sections in two washes of 100% ethanol for 10 min each.

4. Incubate sections in two washes of 95% ethanol for 10 min each.

5. Wash sections two times in dH2O for 5 min each.

6.Antigen retrieval: For Citrate: Heat slides in a microwave submersed in 1X citrate unmasking solution until boiling is initiated; continue with 10 min at a sub-boiling temperature (95°-98°C). Cool slides on bench top for 30 min.

Staining

1. Wash sections in dH2O three times for 5 min each.

2. Incubate sections in 3% hydrogen peroxide for 10 min.

3. Wash sections in dH2O two times for 5 min each.

4. Wash sections in wash buffer for 5 min.

5. Block each section with 100–400 µl of blocking solution for 1 hr at room temperature.

6. Remove blocking solution and add 100–400 µl primary antibody diluent in to each section. Incubate overnight at 4°C.

7. Remove antibody solution and wash sections with wash buffer three times for 5 min each.

8. Cover section with 1–3 drops HRPas needed. Incubate in a humidified chamber for 30 min at room temperature.

9. Wash sections three times with wash buffer for 5 min each.

10. Add DAB Chromogen Concentrate to DAB Diluent and mix well before use.

11. Apply 100–400 µl DAB to each section and monitor closely. 1–10 min generally provides an acceptable staining intensity.

12. Immerse slides in dH2O.

13. If desired, counterstain sections with hematoxylin.

14. Wash sections in dH2O two times for 5 min each.

15. Dehydrate sections: Incubate sections in 95% ethanol two times for 10 sec each; Repeat in 100% ethanol, incubating sections two times for 10 sec each; Repeat in xylene, incubating sections two times for 10 sec each.

16. Mount sections with coverslips and mounting medium.

Datasheet & SDS

Biological Description

Specificity
Mast Cell Chymase Antibody (Rabbit mAb) [C20M13] detects endogenous levels of total Mast Cell Chymase protein.

Uniprot ID
P23946

Clone
C20M13

Synonym(s)
Alpha-chymase; Chymase; chymase 1; chymase 1, mast cell; chymase, heart; chymase, mast cell; CMA1; CYH; CYM; Mast cell protease I; MCT1; MGC119890; MGC119891

Background
Mast cell chymase (chymase 1, CMA1) is a chymotrypsin-like serine protease stored in secretory granules of connective tissue–type mast cells and released upon activation, where it functions as a multifunctional effector enzyme that processes peptides, cytokines, and matrix components at sites of inflammation and tissue remodeling. The enzyme adopts the typical trypsin/chymotrypsin fold with a catalytic His–Asp–Ser triad in a substrate-binding cleft that prefers aromatic residues at the P1 position, and its heparin-dependent packing into mast cell granules positions chymase for rapid, localized proteolysis after degranulation. Angiotensin I represents a key physiological substrate, and human chymase efficiently converts angiotensin I to angiotensin II in the interstitial space, providing a major non–ACE pathway for angiotensin II generation in the heart and vasculature and contributing to local regulation of vascular tone, cardiac remodeling, and atherogenesis. Chymase also processes components of the extracellular matrix and matrix-regulating systems, including activation of matrix metalloproteinases and processing of type I procollagen, which link mast cell degranulation to collagen turnover, fibrotic matrix deposition, and structural changes in the vessel wall and parenchymal organs. Cytokine and growth factor bioavailability is strongly influenced by chymase, which can convert pro–IL‑1β to its active form, degrade IL‑4, and induce release of membrane-bound stem cell factor, thereby modulating local inflammatory cell recruitment, T helper cell polarization, and mast cell survival in a feedback-sensitive manner. Chymase functions as a chemoattractant for leukocytes and promotes migration of eosinophils and other inflammatory cells through protease-activated mechanisms and through remodeling of pericellular matrix, integrating mast cell activation with downstream recruitment and activation of effector leukocytes in allergic and chronic inflammatory settings. In airway disease, mast cell chymase contributes to airway smooth muscle and submucosal remodeling by degrading pericellular matrix, stimulating collagen fibril formation, and enhancing TGF‑β activation, aligning chymase activity with bronchial hyperresponsiveness, airway wall thickening, and features of asthma and chronic obstructive pulmonary disease. Cardiovascular pathologies, including hypertension, myocardial infarction, aneurysm formation, and valvular disease, are associated with increased mast cell chymase activity, where its angiotensin II–generating capacity, matrix-modifying actions, and pro-fibrotic signaling roles converge to drive adverse remodeling, neovascularization, and plaque instability.

Background

Mast cell chymase (chymase 1, CMA1) is a chymotrypsin-like serine protease stored in secretory granules of connective tissue–type mast cells and released upon activation, where it functions as a multifunctional effector enzyme that processes peptides, cytokines, and matrix components at sites of inflammation and tissue remodeling. The enzyme adopts the typical trypsin/chymotrypsin fold with a catalytic His–Asp–Ser triad in a substrate-binding cleft that prefers aromatic residues at the P1 position, and its heparin-dependent packing into mast cell granules positions chymase for rapid, localized proteolysis after degranulation. Angiotensin I represents a key physiological substrate, and human chymase efficiently converts angiotensin I to angiotensin II in the interstitial space, providing a major non–ACE pathway for angiotensin II generation in the heart and vasculature and contributing to local regulation of vascular tone, cardiac remodeling, and atherogenesis. Chymase also processes components of the extracellular matrix and matrix-regulating systems, including activation of matrix metalloproteinases and processing of type I procollagen, which link mast cell degranulation to collagen turnover, fibrotic matrix deposition, and structural changes in the vessel wall and parenchymal organs. Cytokine and growth factor bioavailability is strongly influenced by chymase, which can convert pro–IL‑1β to its active form, degrade IL‑4, and induce release of membrane-bound stem cell factor, thereby modulating local inflammatory cell recruitment, T helper cell polarization, and mast cell survival in a feedback-sensitive manner. Chymase functions as a chemoattractant for leukocytes and promotes migration of eosinophils and other inflammatory cells through protease-activated mechanisms and through remodeling of pericellular matrix, integrating mast cell activation with downstream recruitment and activation of effector leukocytes in allergic and chronic inflammatory settings. In airway disease, mast cell chymase contributes to airway smooth muscle and submucosal remodeling by degrading pericellular matrix, stimulating collagen fibril formation, and enhancing TGF‑β activation, aligning chymase activity with bronchial hyperresponsiveness, airway wall thickening, and features of asthma and chronic obstructive pulmonary disease. Cardiovascular pathologies, including hypertension, myocardial infarction, aneurysm formation, and valvular disease, are associated with increased mast cell chymase activity, where its angiotensin II–generating capacity, matrix-modifying actions, and pro-fibrotic signaling roles converge to drive adverse remodeling, neovascularization, and plaque instability.

References
https://pubmed.ncbi.nlm.nih.gov/23016684/ https://pubmed.ncbi.nlm.nih.gov/17498057/

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%

Mast Cell Chymase Antibody (Rabbit mAb) [C20M13]

Usage Information

Experimental Methods

Datasheet & SDS

Biological Description

Tech Support